Amgen
AMGN,
has obtained approval from the U.S. Food and Drug Administration for Wezlana, its therapy for a number of inflammatory ailments.
Wezlana was permitted as a biosimilar to and interchangeable with Stelara for treating adults with reasonable to extreme plaque psoriasis, energetic psoriatic arthritis, reasonably to severely energetic Crohn’s illness and reasonable to severely energetic ulcerative colitis.
The therapy can be permitted for treating sufferers 6 years and older with reasonable to extreme plaque psoriasis and energetic psoriatic arthritis.
A biosimilar is a therapy that has no clinically significant distinction from one other therapy already permitted by the FDA.
Source web site: www.marketwatch.com
